csirt@kutim:~/threat-intel/cve/CVE-2026-39359

Katalog CVE

CVSS 7.5 · High EPSS 0,36%

Kerentanan Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') pada wazuh. Skor CVSS 3.1 7.5 (High) menurut github.com.

Deskripsi (NVD)

Wazuh is a free and open source platform used for threat prevention, detection, and response. In versions 4.0.0 through 4.10.3 and 4.11.0 through 4.14.4, a logic flaw affects the Wazuh Manager's enrollment daemon (authd) and synchronization daemon (remoted). The authd process allows agents to select a group during enrollment but does not filter path traversal sequences such as "..." While the manager checks for the group directory using wopendir(), the ".." sequence references the parent directory (/var/ossec/etc), allowing it to pass validation. After the malicious group is accepted and stored in the manager's global database, the remoted process uses this unchecked value to build paths for agent configuration synchronization. As a result, sensitive files from /var/ossec/etc, such as client.keys, ossec.conf, and internal certificates, are included in the agent's shared configuration stream and exposed to the attacker. This issue has been fixed in versions 4.10.4 and 4.14.5.

Rincian

Terbit di NVD
17 Juli 2026
Terakhir diubah
20 Juli 2026
Status NVD
Analyzed
CVSS 3.1
7.5 (High), sumber github.com
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-22: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')
EPSS (30 hari)
0,36% peluang dieksploitasi; lebih tinggi dari 27,9% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
wazuh wazuh Versi 4.0.0 hingga sebelum 4.10.4
wazuh wazuh Versi 4.11.0 hingga sebelum 4.14.5

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.